Evidence map›Paper›PMID 40041916›Full record

ArticleActa pharmaceutica Sinica. B2025

"Relative symmetry with electronegativity of different key-groups" strategy for MRGPRX2 antagonist design and its effect on antigen-induced pulmonary inflammation.

Jiayu Lu, Zhaomin Xia, Yongjing Zhang, He Wang, Wen Yang, Siqi Wang, Nan Wang, Yun Liu, Huaizhen He, Cheng Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiayu LuSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Zhaomin XiaSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Yongjing ZhangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
He WangKey Laboratory of Synthetic and Natural Functional Molecule Chemistry (Ministry of Education), College of Chemistry and Materials Science, Northwest University, Xi'an 710069, China.
Wen YangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Siqi WangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Nan WangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Yun LiuDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Huaizhen HeSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Cheng WangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Langchong HeSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MRGPRX2 antagonists possess the potential for the treatment of allergic rhinitis, atopic dermatitis, and chronic urticaria. Previously, we identified a class of diaryl urea (DPU) MRGPRX2 antagonists with sub-micromolar IC

Indexed as

AntagonistAntiallergic activityAntigen-induced pulmonary inflammationDiaryl ureaElectrostatic complementarityMRGPRX2Relative symmetry with electronegativityStructure–activity relationships

Identifiers

PMID40041916
PMCPMC11873639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.